Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Wolverine Stack is the marketing name for a commercial pre-mixed blend of two peptides — BPC-157 and TB-500 — co-lyophilized in a single vial. It is the most common two-peptide combination on the research-peptide market and is sold under several variant names (BPC/TB Blend, BPC-TB-500 Combo, and others). A typical 10 mg vial contains 5 mg of each peptide; a 20 mg vial usually contains 10 mg of each.
The product is marketed within research channels for tendon, ligament, and connective-tissue research protocols. The combination has not been studied as a single product in any clinical trial — the supporting evidence for both peptides comes entirely from separate preclinical work.
History
The pairing of BPC-157 and TB-500 became popular in the research-peptide community in the mid-2010s when veterinary use of TB-500 in racehorses spread into human research-peptide channels and BPC-157 was widely discussed in rodent tendon-healing studies. Vendors began offering pre-mixed vials shortly after. The "Wolverine" branding — a reference to the Marvel character's accelerated healing — emerged through marketing and is not used in any scientific literature.
Component histories:
- BPC-157: a 15-amino-acid synthetic fragment of a human gastric juice protein, characterized by the Sikiric laboratory in Zagreb starting in 1991.
- TB-500: a 7-amino-acid fragment (residues 17–23) of Thymosin Beta-4, originally used in equine veterinary medicine for injury rehabilitation.
Regulatory status
The Wolverine Stack has no approval anywhere in the world. BPC-157 was placed in FDA 503A Category 2 in November 2023, effectively barring U.S. compounding pharmacies from preparing it for patients. TB-500 has been on the WADA prohibited list (S2) since 2011. The blend is sold by research-chemical suppliers labeled not for human use.
How researchers describe its action
Because the combined product has not been studied, the published mechanism descriptions apply only to the individual components:
- BPC-157 is described as a modulator of nitric oxide signaling, an upregulator of VEGFR2, and an enhancer of growth hormone receptor expression in tendon cells. The Sikiric lab has reported effects on tendon outgrowth, cell survival, and migration in rodent models.
- TB-500 retains the actin-binding sequence of Thymosin Beta-4 and is described in the parent protein's literature as a promoter of cell migration into wound beds, with secondary angiogenic and anti-inflammatory effects.
No published study has examined whether the two peptides interact pharmacologically or whether their combined kinetics differ from the components dosed separately.
Half-life and dosing intervals
- BPC-157: approximately 15–30 minutes circulating half-life.
- TB-500: approximately 1.5–3 hours circulating half-life.
Observational protocols circulated by users typically describe subcutaneous injection once daily or every other day, with a loading phase in the first 4–6 weeks and a reduced maintenance schedule afterward. Total per-injection mass typically falls in the 1–3 mg range across both peptides. These regimens are not derived from any controlled human study and should not be interpreted as established therapeutic doses.
Reconstitution example
Wolverine Stack vials are typically 10 mg (5 mg BPC-157 + 5 mg TB-500) or 20 mg (10 mg each). A 20 mg vial reconstituted with 2 mL of bacteriostatic water yields a total peptide concentration of 10 mg/mL. On a 1 mL U-100 insulin syringe, 10 units (0.10 mL) contains 1 mg of total peptide mass — 0.5 mg of BPC-157 and 0.5 mg of TB-500.
Vial's calculator handles total-vial-to-syringe-unit math directly; per-component mass depends on the labeled ratio.
What to know
- No combined clinical data. The two-peptide blend has not been studied as a unit in any published clinical or preclinical trial. All efficacy claims must be referenced back to component literature.
- Component regulatory status. BPC-157 cannot legally be compounded for U.S. patients; TB-500 is banned in competitive sport.
- Storage. Refrigerate lyophilized vials. After reconstitution, refrigerate and use within four weeks per the stability data published for both component peptides.
- Reported side effects. User reports of the component peptides describe injection-site irritation, transient headaches with BPC-157, and lethargy or mild flu-like symptoms during high-dose TB-500 phases. No controlled human safety profile exists for the combined product.
Sources
- 1.Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- 2.Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology.
- 3.Goldstein AL et al. (2012). Thymosin β4: a multifunctional regenerative peptide. Expert Opinion on Biological Therapy.
- 4.FDA 503A Bulk Drug Substances list — Category 2 (November 2023, BPC-157).
- 5.WADA 2024 Prohibited List — peptide hormones (S2).